Skip to main content
LFCR
NASDAQ Life Sciences

Lifecore Q3 Revenue Falls 18.6% to $25.3M; $40.1M Net Loss Driven by Non-Cash Derivative Mark

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$6.38
Mkt Cap
$243.356M
52W Low
$3.625
52W High
$8.98
52W Position info
76% above low
Off High info
29% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

LFCR sits 76% above its 52-week low of $3.625.

Summary

Lifecore's Q3 revenue fell 18.6% to $25.3 million and the net loss widened to $40.1 million, but $31.3 million of that loss is a non-cash derivative remeasurement; Adjusted EBITDA rose to $4.0 million. Results land as the $6.28-per-share Webster Equity Partners merger goes to a stockholder vote.


Key Events · Earnings and Guidance · LFCR

  • Q3 Revenue Down 18.6%

    Total revenues were $25.3 million versus $31.1 million a year earlier; CDMO revenue fell 18% to $17.8 million and HA manufacturing fell 19% to $7.5 million. Nine-month revenue was $82.7 million, down 21.8%.

  • Net Loss Is Mostly Non-Cash

    The $40.1 million Q3 net loss ($1.08 per diluted share) includes a $31.3 million non-cash change in fair value of the related-party debt derivative liability — a mark-to-market entry, not a cash outflow and not new dilution. Adjusted EBITDA rose to $4.0 million from $3.1 million.

  • Cash Generation and Liquidity

    Nine-month operating cash flow was $9.5 million and free cash flow $6.9 million. The quarter ended with roughly $38.0 million of liquidity: $23.0 million of cash plus $15.0 million of revolver availability.

  • New Business Wins for 2027

    Two technology transfer projects were signed in Q3 (one supporting PPQ batches for a biotech NDA, one for a large pharma's marketed product), plus three early-Q4 development programs including a Phase 2 product with a top-20 global pharma. Management expects revenue contribution beginning in 2027.


Analysis · LFCR · Life Sciences

Revenue kept shrinking — total revenues fell 18.6% to $25.3 million and CDMO revenue dropped 18% — but the headline $40.1 million net loss is mostly accounting, not cash: it includes a $31.3 million non-cash change in the fair value of the related-party debt derivative liability, a mark-to-market entry that moves with the share price and involves no cash outflow and no new shares. Strip that out and Adjusted EBITDA actually improved to $4.0 million from $3.1 million, and the company generated $9.5 million of operating cash flow over nine months. The real constraint remains the balance sheet: $38.0 million of liquidity against a $50.2 million preferred stock redemption obligation previously disclosed as due December 28, 2026. All of this is backdrop to the pending $6.28-per-share cash merger with Webster Equity Partners, which stockholders vote on at the special meeting whose record date was today, November 4, 2026 — the deal price, not the quarterly print, is what sets the stock's value.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LFCR was trading at $6.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $243.4M. The 52-week trading range was $3.63 to $8.98. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LFCR - Latest Insights

LFCR
Oct 30, 2026, 5:26 PM EDT
Filing Type: PREM14A
Importance Score:
8
Price at Filing: $6.40
Real-time Price: $6.37 info
Change: -$0.030 (-0.47%) info
Market Cap: $241.46M info
LFCR
Sep 29, 2026, 4:15 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $6.52
Real-time Price: $6.37 info
Change: -$0.150 (-2%) info
Market Cap: $241.46M info
LFCR
Sep 28, 2026, 5:41 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $6.62
Real-time Price: $6.37 info
Change: -$0.250 (-4%) info
Market Cap: $241.46M info
LFCR
Sep 28, 2026, 8:56 AM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $4.30
Real-time Price: $6.37 info
Change: +$2.07 (+48%) info
Market Cap: $241.46M info
LFCR
Sep 28, 2026, 8:53 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.30
Real-time Price: $6.37 info
Change: +$2.07 (+48%) info
Market Cap: $241.46M info